Title	Effects of sesamin on the biosynthesis of chondroitin sulfate proteoglycans in human articular chondrocytes in primary culture
Author(s)	Pothacharoen, Peraphan; Najarus, Sumet; Settakorn, Jongkolnee; Mizumoto, Shuji; Sugahara, Kazuyuki; Kongtawelert, Prachya
Citation	Glycoconjugate Journal, 31(3), 221-230 https://doi.org/10.1007/s10719-013-9514-6
Issue Date	2014-04-01
Doc URL	http://hdl.handle.net/2115/58536
Rights	The final publication is available at link.springer.com
Type	article (author version)
File Information	GLYC-D_31_p221-.pdf

[Instructions for use](#)

Glycoconjugate Journal

Effects of Sesamin on the Biosynthesis of Chondroitin Sulfate Proteoglycans in Human Articular Chondrocytes in Primary Culture --Manuscript Draft--

Manuscript Number:	GLYC-D-13-00061
Full Title:	Effects of Sesamin on the Biosynthesis of Chondroitin Sulfate Proteoglycans in Human Articular Chondrocytes in Primary Culture
Article Type:	Original Research
Keywords:	Sesamin, Proteoglycan biosynthesis, aggrecan, human articular chondrocyte
Corresponding Author:	Prachya Kongtawelert, Ph.D. Thailand Excellence Center for Tissue Engineering and Stem Cells Muang, Chiang Mai THAILAND
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Thailand Excellence Center for Tissue Engineering and Stem Cells
Corresponding Author's Secondary Institution:	
First Author:	Peraphan Pothacharoen, Ph.D.
First Author Secondary Information:	
Order of Authors:	Peraphan Pothacharoen, Ph.D.
	Sumett Najarus, M.S.
	Jongkolnee Settakorn, M.D.
	Shuji Mizumoto, Ph.D.
	Kazuyuki Sugahara, Ph.D.
	Prachya Kongtawelert, Ph.D.
Order of Authors Secondary Information:	

Effects of Sesamin on the Biosynthesis of Chondroitin Sulfate Proteoglycans in Human Articular Chondrocytes in Primary Culture

Peraphan Pothacharoen¹, Sumet Najarus¹, Jongkolnee Settakorn², Shuji Mizumoto³, Kazuyuki Sugahara^{3*}, Prachya Kongtawelert^{1*}

¹Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Intavaroros Road, Sripoom, Muang, Chiang Mai, 50200, Thailand

²Department of Pathology, Faculty of Medicine, Chiang Mai University, Intavaroros Road, Sripoom, Chiang Mai, 50200, Thailand

³Proteoglycan Signaling and Therapeutics Research Group, Faculty of Advanced Life Science, Hokkaido University Graduate School of Life Science, Sapporo, 001-0021, Japan

*Corresponding author: Prachya Kongtawelert, prachya.kongtawelert@gmail.com
Kazuyuki Sugahara, k-sugar@sci.hokudai.ac.jp

address: 110 Intavaroros, Amphur Muang, Chiang Mai 50200, Thailand.

Running title: Effects of Sesamin on the Proteoglycan Biosynthesis in Human Chondrocytes

ABSTRACT

Osteoarthritis (OA) is a degenerative joint disease that progressively causes a loss of joint functions and the impaired quality of life. The most significant event in OA is a high degree of degradation of articular cartilage accompanied by the loss of chondroitin sulfate-proteoglycans (CS-PGs). Recently, the chondroprotective effects of sesamin, the naturally occurring substance found in sesame seeds, have been proved in a rat model of papain-induced osteoarthritis. We hypothesized that sesamin may be associated with possible promotion of the biosynthesis of CS-PGs in human articular chondrocytes. The aim of the study was to investigate the effects of sesamin on the major CS-PG biosynthesis in primary human chondrocyte. The effects of sesamin on the gene expression of the PG core and the CS biosynthetic enzymes as well as on the secretion of glycosaminoglycans (GAGs) in monolayer and pellet culture systems of articular chondrocytes. Sesamin significantly increased the GAGs content both in culture medium and pellet matrix. Real-time-quantitative PCR showed that sesamin promoted the expression of the genes encoding the core protein (*ACAN*) of the major CS-PG aggrecan and the biosynthetic enzymes (*XYLT1*, *XYLT2*, *CHSY1* and *CHPF*) required for the synthesis of CS-GAG side chains. Safranin-O staining of sesamin treated chondrocyte pellet section confirmed the high degree of GAGs accumulation. These results were correlated with an increased level of secreted GAGs in the media of cultured articular chondrocytes in both culture systems. Thus, sesamin would provide a potential therapeutic strategy for treating OA patients.

Key Words: Sesamin, human articular chondrocytes, chondroitin sulfate, proteoglycan, glycosaminoglycan, osteoarthritis

Introduction

Osteoarthritis (OA) is the most important joint diseases in the field of orthopedics and occurs worldwide with the highest prevalence. Moreover, OA is associated with an extremely high economic burden, which is largely attributable to the effects of disability and the expense of the treatments as well as the impaired quality of life[1]. The disease is characterized by a progressive loss of articular cartilage that causes chronic pain and compromises joint function. These events are accompanied by changes in a complex network of biochemical factors, including proteolytic enzymes, which cause a breakdown of the cartilage macromolecules especially collagen and a major chondroitin sulfate (CS)-proteoglycan (PG), aggrecan[2, 3]. Several studies recently reported that the degradation of CS-PGs was correlated with the severity of OA[4]. The current OA treatment is primarily focused on a symptomatic relief by the use of rapidly acting drugs, especially NSAIDs (non-steroidal anti-inflammatory drugs)[5]. NSAIDs increase the risk of upper gastrointestinal adverse effects and does not affect the underlying pathogenesis of the disease [6]. Hence, there has been a continuous search for new and better drugs for OA. There has been increase in the use of symptomatic slow acting drugs such as glucosamine, CS and diacetylrhein (diacerein)[7]. These drugs could favor anabolic processes in the OA cartilage and contribute to a delayed progression of the disease via inhibition of the catabolic processes[8]. Currently, there are very few safe drugs or innovations that have been proved to restore cartilage or curtail the disease processes[9]. Thus, truly disease-modifying and safer agents for the management of OA are still desired. Many studies have shown that alternative herbal medicines or phytochemicals have possible chondroprotective properties and are interesting candidates for the non-pharmacological intervention. Thus, herbal medicines may be suitable candidates for OA treatment.

Sesame (*Sesamum indicum* L.) has been used, extensively, as a traditional food in eastern countries. Sesame seeds and oil are widely used in cooking[10]. Sesame seeds contain a group of compounds called lignans, which are one of the major classes of phytoestrogens, and play an important role in health-promoting effects. They have the pharmacological properties including anti-inflammatory

1 effects[11], antioxidant activity[12], antihypertensive effects[13], apoptosis-induction
2 in tumor cells [14], enhancing antioxidant activity of vitamin E[15], lowering
3 cholesterol levels[16], improving fatty acid metabolism[17], and neuroprotective
4 effects against hypoxia[18]. Recently, we reported that sesamin treatment *in vitro*
5 reversed pathological changes in OA cartilage: reduced the disorganization of
6 chondrocytes in cartilage, increased cartilage thickness and decreased losses of type II
7 collagen and CS-PGs[11].
8
9
10
11
12

13 In the past decade, there has been no study related to chondroprotection that
14 has focused on the effects on the genes of biosynthesis of CS-PGs. Therefore, here we
15 studied using cultured HAC (human articular chondrocytes) systems, the effects of
16 sesamin on the gene expression of the core protein of the major CS-PG, aggrecan and
17 on the glycosyltransferases required for the attachment of CS side chains on the
18 aggrecan core protein. Aggrecan core protein is encoded by the *ACAN* gene, which is
19 highly expressed in cartilagenous tissues[19-22]. *XYLT1* and *XYLT2* encode
20 xylosyltransferase I (XylT1) and xylosyltransferase II (XylT2), respectively, which
21 catalyze the initial enzymatic reaction in the assembly of GAGs onto core proteins.
22 This addition of a xylose to specific serine residues in the core protein is a rate-
23 limiting step for aggrecan biosynthesis[19, 23, 24]. *CHSY1* and *CHPF* encode
24 chondroitin synthase 1 (ChSy1) and chondroitin polymerizing factor (ChPF),
25 respectively. Their heterodimeric complex exhibits chondroitin polymerase
26 activity[25, 26], which extends the CS chain by adding alternate GalNAc and GlcUA
27 sugar residues from nucleotide sugar substrates. To investigate effects of sesamin on
28 the expression of the genes encoding aggrecan (*ACAN*) and CS biosynthetic enzymes
29 including *XYLT1*, *XYLT2*, *CHSY1*, and *CHPF* as well as the content of GAGs, two
30 different HAC culture systems, monolayer and pellet cultures, were utilized in this
31 study. It is notable that full production of CS-GAG is essential for healthy cartilage
32 development as genetic defects of certain glycosyltransferases and sulfotransferases
33 involved in the biosynthesis of CS-GAGs cause developmental delay, short stature,
34 generalized osteopenia, chondrodysplasia, craniofacial dysmorphism, and OA[22,
35 27].
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Material and methods

Chemicals

CS-C and the Hoechst 33258 dye were purchased from Sigma-Aldrich (St. Louis, MO, USA). Custom primers for RT-qPCR were purchased from Bio-Rad (Hercules, CA, USA). illustra RNAspin Mini RNA Isolation Kit was purchased from GE Healthcare (Buckinghamshire, UK). iScript[™] Reverse Transcription Supermix and SsoFast[™] EvaGreen[®] Supermix were purchased from Bio-Rad (Hercules, CA, USA). The preparation of Sesamin was described by T. Phitak *et al*[11].

Cells

HAC from non-osteoarthritis joints were harvested from articular cartilage of 18-45 year-old patients, and chondrocytes were isolated according to a standard protocol. Informed consents were obtained from all the patients, and all procedures of the chondrocyte isolation were approved by the Ethical Committee of Faculty of Medicine, Chiang Mai University (approval no. 070CT111016).

Detroit 551 is a human skin fibroblast cell line purchased from ATCC[®] (CCL-110). Detroit 551 was used as a negative control cell line because the main CS-PG of Detroit 551 is versican but not aggrecan[28].

Cell culture and treatment

The original morphology of HAC is a spherical shape. However, after isolation, their *in vitro* expansion is intrinsically associated with cellular de-differentiation and reduced ability to re-differentiate. The de-differentiation occurs when chondrocytes are cultured under conditions allowing them to attach and spread on a two-dimensional (2D) surface in a monolayer culture. In this environment, chondrocytes gradually lose their spherical shape and acquire an elongated fibroblast-like morphology. These morphologic alterations are accompanied by profound biochemical changes, as indicated by the reduction or total loss of aggrecan and the synthesis of type II collagen with the increased synthesis of versican CS-PG and type I collagen. However, de-differentiated chondrocytes have the capacity to re-

differentiate when transferred into an environment supporting a spherical morphological formation (a pellet culture)[29].

For monolayer cultures, 4.5×10^4 cells/well were cultured in the Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal calf serum (FBS). Cells were maintained in culture in a humidified incubator with 5% CO_2 at 37°C . The culture medium was collected for measuring GAGs.

For pellet cultures, 5.0×10^5 cells/pellet were formed with 1 ml medium in a 15 ml conical culture tube by being spun for 5 min at $160 \times g$, and were grown as cell pellets in the medium: 10% FCS/DMEM, Insulin-Transferrin-Selenium (ITS 1x), 25 $\mu\text{g/ml}$ ascorbic acid 2-phosphate and 10^{-7} M dexamethasone. Pellets were allowed to grow in a humidified incubator (37°C , 5% CO_2) for 21 days with regular medium changes (every 2-3 days). The culture medium was collected for measuring GAGs, whereas the cell pellets were digested with papain to determine the content of GAGs and DNAs. GAGs and DNAs in each culture medium and the supernatant fluid of the papain digest of the pellet were quantified using 1,9-dimethylmethylene blue (DMMB), whereas DNAs in the papain digests were determined using Hoechst 33258 as described below.

Methylthiazole tetrazolium (MTT) assay

5.0×10^4 cells were plated in triplicate in 96-well plates and incubated overnight. The cells were treated with various concentrations of sesamin (0-10 μM) for 24 h. After incubation, culture media were discarded and replaced with 100 μl 0.5 mg/ml MTT for 4 h. The MTT agent was discarded and 100 μl of dimethyl sulfoxide was added in each well to solubilize the formazane crystals. The absorbance was measured at 540 nm using a microplate reader. Percent of survived cells was calculated as follows: Percentage of survival = (OD. of sample $\times$ 100)/ OD. of control.

Quantification of GAGs with DMMB

GAGs were determined using DMMB with CS-C (0-60 $\mu\text{g/ml}$) as a standard. 200 μl of a DMMB solution was added to 50 μl of a sample (a conditioned medium or a supernatant fluid recovered from a papain digest of the cell pellet) and the standard prior to reading absorbance values at 525 nm in a spectrophotometer for microplates.

Quantification of DNA using Hoechst 33258

Papain-digested individual samples (20 μ L each) were added to 2 ml of a dye/buffer solution, and the fluorescence of the samples was measured using the excitation and emission wavelengths of 450 and 555 nm, respectively. A standard curve was generated using known concentrations of standard DNA (0 - 200 ng/ml).

Reverse transcribed quantitative-polymerase chain reaction (RT-qPCR)

RT-qPCR was used to examine the gene expression in the monolayer and pellet cultures of HAC treated with or without sesamin. Total RNA was isolated using an RNA extraction kit following the manufacturer's protocol (GE Healthcare). Total RNA (1 μ g) was converted to cDNA using iScript[™] Reverse Transcription Supremix. For determination of the gene expression, the reaction setup of SsoFast[™] EvaGreen[®] Supremix and Real-Time PCR system was used. Gene expression was measured in triplicate in three separate experiments and relative gene expression was converted using the $2^{-\Delta\Delta Ct}$ method[30] against the internal control *GAPDH* as a house-keeping gene. Primer sequences are shown in Table 1.

Hematoxylin-eosin (H&E) and Safranin-O stainings

The pellets obtained at day 21 were collected in phosphate-buffered saline containing 0.4% formaldehyde at 4°C. The pellets were processed into paraffin wax blocks, sectioned, and 4 μ m sections were stained with H&E for assessment of cell/tissue morphology and with Safranin-O for the localization of GAGs. The stained sections were mounted on glass slides and were observed at 400x magnification by light microscopy.

Statistical analysis

All values are given as mean $\pm$ standard deviation from triplicate samples of three independent experiments. The non-parametric test (Mann-Whitney U test) was used to compare treated and untreated control cells. Differences were considered statistically significant when $p < 0.05$ and $p < 0.01$.

Results

Investigation of cytotoxic effects of sesamin on primary HAC and Detroit 551 cells

Prior to an investigation of the effects of sesamin on the biosynthesis of CS-PGs by HAC, the cytotoxicity of sesamin was first examined. The presence of sesamin at concentrations (0.16 - 10 μ M) did not affect cell viability (>80%) compared with untreated control cells. Therefore, based on the methylthiazole tetrazolium (MTT) assay, sesamin at these concentrations was not toxic to either HAC or Detroit 551 cells (data not shown).

Time-course characterization of the expression of the genes encoding aggrecan (ACAN) and CS biosynthetic enzymes (XYLT1, XYLT2, CHSY1 and CHPF)

Cultured HAC treated with sesamin for 24 h were collected at 12 time points and cell lysates were used for RNA extraction and gene expression analysis by RT-qPCR. At 45 min of treatment, 2 μ M sesamin significantly up-regulated the expression of *ACAN*, *XYLT1*, *XYLT2*, *CHSY1* and *CHPF* with 2.56, 2.50, 3.11, 2.71 and 2.37-fold, respectively, when compared with untreated cells (data not shown). Moreover, the expression of these genes in HAC cells treated with sesamin for 5, 6 and 20 h was similarly up-regulated (data not shown). The 45-min time point was then chosen for the treatment in the further experiments because it was the earliest time point showing a significant change of the gene expression encoding ACAN and CS biosynthetic enzymes.

Investigation of the effects of sesamin on the expression of the genes involved in the synthesis of CS-PGs in HAC and Detroit 551 cells

In monolayer HAC cultures, it was found that the treatment with sesamin at a high dose (2 μ M) could significantly increase the expression of *ACAN*, *XYLT1*, *XYLT2*, *CHSY1* and *CHPF* genes with 2.62, 2.36, 3.00, 2.96, and 2.41-fold, respectively, when compared with untreated cells (Figs. 1A-E). Moreover, sesamin selectively increased the expression of all tested genes involved in the biosynthesis of CS-PGs in a dose dependent manner only in HAC, but not in Detroit 551 cells. Detroit 551 cells were used as control cells because we were interested in

investigating the effects of sesamin on the gene expression of aggrecan CS-PG and the CS biosynthetic enzymes, whereas the Detroit 551 cell line is derived from normal human skin and expresses versican CS-PG as the predominant PG, but not aggrecan[31, 32].

In pellet cultures, HAC and Detroit 551 cells were cultured in 3D (5×10^5 cells per pellet) in chondrogenic media and treated with 0.5, 1 and 2 μ M sesamin for 21 days. Conditioned media and pellets were collected every 3 and 7 days for analyzing GAGs (on day 1, 4, 7, 10, 14, 16, 19 and 21) and the gene expression (on day 1, 7, 14 and 21), respectively.

The gene expression of proteins involved in the CS biosynthesis was determined every 7 days during the treatment of the HAC pellet culture for 21-days with sesamin. Sesamin (at 1 and 2 μ M) up-regulated the expression of all tested genes involved in the CS synthesis on day 14. The expressions of *ACAN*, *XYLT1*, *XYLT2*, *CHSY1* and *CHPF* at 1 μ M sesamin increased 1.89, 2.66, 2.30, 3.29, and 3.07-fold, respectively, compared with untreated cells. Upon treatment with 2 μ M sesamin, the expression of these genes increased 3.00, 3.34, 3.79, 5.99, and 3.66-fold, respectively, when compared with untreated cells (Fig. 2). In addition, under some conditions of the sesamin treatment, for example on day 7, a significant increase was observed in the expression of the following genes encoding the CS biosynthetic enzymes: *XYLT2* at 2 μ M sesamin (1.8-fold of untreated cells) (Fig. 2C) and *CHSY1* at 1 and 2 μ M sesamin (1.9 and 2.4-fold of untreated cells, respectively) (Fig. 2D). On day 21, however, the expression of the genes encoding these enzyme proteins showed no significant difference between sesamin-treated and untreated pellet cultures. Notably, sesamin showed the specific increase in the expression of the genes encoding the enzyme proteins for CS biosynthesis in HAC cultures, whereas it exhibited no significant effect on the pellet culture of the Detroit 551 cells.

Investigation of the effects of sesamin on GAGs secreted in the culture media

Since we previously showed that sesamin can maintain the thickness of OA-cartilage and give high density of Safranin-O staining in an OA-induced rat model (Phitak et al., 2012), the effects of sesamin on the secretion of GAGs was investigated

1 in the HAC culture media. In monolayer cultures, it was found that sesamin (at 0.5,
2 1.0 and 2.0 μM) could significantly increase the secretion of GAGs into the culture
3 media of HAC 1.2, 1.2, and 1.4-fold, respectively, when compared with untreated
4 cells (Fig. 1F). These results correlated well with those of the gene expression of the
5 CS biosynthetic enzymes tested. In contrast, sesamin had no effect on the Detroit 551
6 cell line.
7
8
9

10
11 Pellets of HAC and D551 cells were cultured in media for 21 days as
12 described in “Experimental Procedures”. The chondrogenic media obtained from the
13 pellets were changed every 3 days, and collected for the measurement of the level of
14 GAGs secreted into the media. The accumulation and variation of GAGs in both types
15 of the cells were analyzed by the DMMB assay. The DNA content ($\mu\text{g/ml}$) was
16 quantified using Hoechst 33258 as an index of the cell number to normalize each
17 GAG value.
18
19
20
21
22
23
24

25 For the pellet culture of Detroit 551 cells, the sesamin treatment gave no
26 significant effect on the accumulation of GAGs in the culture media compared to the
27 untreated cells. In contrast, in the HAC pellets cultured for 10 days, treatments with 1
28 and 2 μM sesamin significantly increased the accumulation of GAGs in the media
29 1.3-fold as compared with the untreated cells (Fig. 3A). The secretion of GAGs into
30 the media was also significantly raised between days 10-16 (Fig. 3C and D). Sesamin
31 at the concentrations of 1 and 2 μM caused an increase in the GAG level in the media
32 as follows: 1 μM sesamin on days 10, 14, and 16 increased the GAG level 1.6, 1.7
33 and 1.3-fold, respectively, as compared with untreated cells (Fig. 3C). Sesamin at 2
34 μM on days 10, 14 and 16 increased the GAG level 1.5, 1.6 and 1.3-fold, respectively,
35 as compared with the untreated cells (Fig. 3D). In addition, the increase in GAGs at 1
36 and 2 μM sesamin on day 14 was correlated with the increase in the expression of the
37 genes encoding the CS biosynthetic enzymes on day 14 (Fig. 2).
38
39
40
41
42
43
44
45
46
47
48
49

50 Sesamin had no significant effect on the secretion of GAGs in the conditioned
51 media of the pellet-cultured Detroit 551 cells (data not shown). GAGs in the collected
52 conditioned media recovered from the pellet cultures of HAC and Detroit 551 cells
53 were determined by the DMMB assay and the DNA content ($\mu\text{g/ml}$) in each cell
54 pellet was measured by the Hoechst assay to normalize the GAG values relative to the
55 cell number. The results indicated that the amount of GAGs in the conditioned media
56
57
58
59
60
61
62
63
64
65

of the HAC pellet after treatment with 1 and 2 μ M sesamin on day 21 was 1.5 and 1.6-fold, respectively, as compared with that of the untreated cell pellet (data not shown). Moreover, treatments with 1 and 2 μ M sesamin showed an elevation of the accumulated GAGs on day 21, 1.5 and 1.7-fold, respectively (data not shown), when compared with those observed on day 1 after treatment with 1 and 2 μ M sesamin.

2-5. Investigation of the effects of sesamin on the accumulation of GAGs in the pellet matrix

GAGs are not only secreted into the culture medium but also accumulate in the pellet matrix. The GAGs in the pellet were analyzed after papain digestion at 60°C for 18 h in order to remove proteins. On days 1 and 21, the papain digest supernatants were collected by centrifugation from HAC and Detroit 551 pellets for measurement of accumulated GAGs. Results were normalized to the cell number following assay of the DNA content (μ g/ml) in each digest.

The results showed that sesamin had no significant effect on accumulation of GAGs in the matrix of the Detroit 551 cell pellet (Fig. 4A). In contrast, the GAG level in the HAC pellet treated with 1 and 2 μ M sesamin increased on day 21, 1.9 and 2.2-fold, respectively (Fig. 4B), when compared with the untreated HAC pellet. Moreover, treatments with 1 and 2 μ M sesamin increased the GAG level on day 21, 2.3 and 2.6-fold, respectively (Fig. 4B), when compared with that observed on day 1 after treatment with 1 and 2 μ M sesamin.

Effects of sesamin on the accumulation of GAGs in the matrix

The Detroit 551 cell pellets and HAC pellets on day 21 were sectioned and stained using hematoxylin and eosin (H&E) as well as Safranin-O for examining the cell morphology and the accumulation of GAGs, respectively. H&E staining showed the morphology characteristic of Detroit 551 skin fibroblasts (data not shown) and chondrocytes (Fig. 5A) in the pellet cultures. It was found that treatments with the sesamin concentrations of 0.5, 1 and 2 μ M did not affect the morphology of the Detroit 551 cells when compared with the untreated controls (data not shown). Sesamin treatments at the concentrations of 0.5, 1 and 2 μ M did not affect the HAC morphology when compared with the untreated controls (Fig. 5A). Thus, sesamin had

no effects on the morphology of either HAC or Detroit 551 cells under the pellet culture conditions.

The GAGs of both fibroblasts and chondrocytes were found to be embedded in the extracellular matrix of the cultured pellets of the Detroit 551 cells (data not shown) and HAC (Fig. 5B). Safranin-O staining revealed that sesamin had no effects on the accumulation of GAGs in the cultured Detroit 551 cell pellet (data not shown). In strong contrast, the HAC pellet cultured at the sesamin concentrations of 1 μ M and 2 μ M markedly increased the intensity of red color in the matrix area of the pellet sections when compared with the untreated counterparts (Fig. 5B), confirming the accumulation of extracellular GAGs. Thus, the GAG analysis and staining showed that sesamin increased GAG production in the HAC pellet.

Discussion

Osteoarthritis (OA) is a progressive degenerative joint disease characterized by cartilage degeneration and an imbalance between the synthesis and degradation of the CS-PG aggrecan, leading to an impairment of joint functions and quality of life. The burden of the disease dramatically impacts health leading to joint replacement[1, 33]. According to the adverse effects of the rapid action drugs for symptomatic relief, there has been an increased use of symptomatic slow acting drugs (chondroprotective drugs or connective tissue structure modifying agents) such as chemically modified tetracyclines, glucosamine (chondroitin sulfate) and diacetylrhein (diacerein)[34, 35]. However, glucosamine is a dietary supplement not a pharmaceutical drug. The most common side effect of the diacerein treatment is diarrhea[36, 37]. Thus, truly disease-modifying and safer agents or dietary supplements for the management of OA are still needed.

The chondroprotective effects of sesamin were previously reported[11]. The present study has revealed for the first time that sesamin increases the HAC anabolism via elevation of aggrecan synthesis as demonstrated by the elevation of the gene expression of *ACAN*, *XYLT1*, *XYLT2*, *CHSY1*, and *CHPF*. The time-course study of the monolayer culture of HAC revealed that the gene expression of all tested CS biosynthetic enzyme genes peaked at 45 min and 5-6 h of sesamin treatments. This

1 was concomitant with a previous report that the expression of *ACAN* was up-regulated
2 at 5 h after mechanical stimulation[38]. In contrast, the pellet culture of HAC showed
3 that the gene expression of all tested CS biosynthetic enzymes gradually increased
4 and peaked at day 14 of sesamin treatments. Shi *et al.* have reported that multiple
5 growth factors stimulated the expression of *ACAN* in articular chondrocytes. The
6 *ACAN* expression peaked at day 3 after treatment with bone morphogenetic protein
7 (BMP)-2 or BMP-7 and at day 5 with insulin-like growth factor (IGF)-1, IGF-2 or
8 transforming growth factor- β 1[39]. These observations indicate that the timing of the
9 up-regulation of *ACAN* can differ when stimulated with different growth factors or
10 with certain plant extracts. Since our results suggested that the effects of sesamin are
11 comparable to those of growth factors, it will be important to investigate if the effects
12 of sesamin are exhibited by activating signaling pathways associated with growth
13 factors.
14
15
16
17
18
19
20
21
22
23

24 To enable an accurate comparison of the quantity of GAGs secreted into the
25 culture media or accumulated in the pellet matrix, the GAG content was normalized
26 to the DNA content. However, in the monolayer culture, the GAG level in the culture
27 media was not normalized because the culture media were collected at 45 min, and
28 this time point was too short for the cells to proliferate since the doubling time of
29 human cells for one cell cycle is approximately 24 h[40].
30
31
32
33
34
35

36 Two different culture methods were used in this study; monolayer and pellet
37 cultures to investigate the effects of sesamin. The monolayer culture has some
38 advantages for cell expansion and in measuring the effects of sesamin on the gene
39 expression involved in CS-PGs biosynthesis for a short time period (within 24 h). The
40 isolated HAC of late passages in monolayer culture will de-differentiate, in this
41 environment, chondrocytes gradually lose their spherical shape and acquire an
42 elongated fibroblast-like morphology. These morphological alterations are
43 accompanied by profound biochemical changes such as the reduction or total loss of
44 the synthesis of aggrecan and type II collagen (cartilage-specific proteins), and by the
45 increase in the synthesis of versican and type I collagen. De-differentiated
46 chondrocytes at low passage (<5) have the capacity to re-differentiate when
47 transferred into an environment supporting a spherical morphology like pellet culture
48 conditions, in which the synthesis of aggrecan and type II collagen are recovered[29].
49 Thus, the pellet culture method was used as a model to investigate the effects of
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

sesamin on HAC with a cell morphology similar to that of chondrocytes in cartilage. The pellet culture was used also to confirm the accumulation of the extracellular matrix by histology.

In the present study, the expression of the genes of the biosynthesis of CS-PGs in HAC was activated by sesamin, which was concomitant with an increase in the up-regulated CS-PG level of the media of both the monolayer and pellet cultures. The rate of biosynthesis of CS-GAGs in chondrocytes is entirely dependent on the supply of the core protein of aggrecan PG encoded by *ACAN*. The biosynthesis of CS-GAGs is controlled by glycosyltransferases including *XYLT*, *CHSY1*, and *CHPF*[41-43]. This was consistent with our previous report that increasing the expression of the transcription factor *SOX9* in HAC resulted in an increase in the GAGs biosynthesis in monolayer and pellet cultures[41]. These observations indicate that the effects of sesamin on the expression of the genes for the CS-PG biosynthesis may be associated with direct effect on *SOX9*. It will be important to investigate the regulation of the expression of the genes encoding CS-PG core proteins and the enzymes for CS biosynthesis through the *SOX9* signaling pathway. Furthermore, it would also be interesting to extend the present study by investigating if sesamin can reverse any of the catabolic effects of inflammatory cytokines on HAC or can reverse changes in the gene expression in HAC isolated from OA patients. This will add to the present study, which examined the effects of sesamin on normal primary HAC from healthy joints.

In conclusion, the present study showed that sesamin had important anabolic effects on aggrecan production by primary cultures of HACs. Sesamin was shown to up-regulate the expression of the genes involved in the biosynthesis of CSPGs: *ACAN*, *XYLT1*, *XYLT2*, *CHSY1*, and *CHPF*. These effects were consistent with the increased secretion of GAGs into the media of the monolayer cultures as well as in 3D pellet cultures. These findings give insights into a possible treatment for OA using sesamin and may form the basis for the new therapeutic strategy using phytochemicals.

Author contribution

All authors have participated in the work as following:

1 PP – drafting of the article, interpretation of the data, final approval of the
2 article, conception and design of the study.
3

4 SN- analysis and interpretation of the data, drafting the article, statically
5 analysis.
6
7

8 JS- Histological analysis and interpretation.
9

10 SM- drafting of the article, final approval of the article.
11

12 KS- final approval of the article, revising for intellectual content, conception
13 and design of the study.
14
15

16 PK-final approval of the article, revising for intellectual content, conception
17 and design of the study.
18
19

20 **Acknowledgements** 21 22 23 24 25

26 The work described in this paper was supported by Center for Innovation in
27 Chemistry: Postgraduate Education and Research Program in Chemistry (PERCH-
28 CIC), and also supported in part by the Japan-Thailand Research Cooperative
29 Program (to K. S. and P. K.) from the Japan Society for the Promotion of Science and
30 the National Research Council of Thailand (JSPS-NRCT).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Reference

1. Krasnokutsky, S., Attur, M., Palmer, G., Samuels, J., Abramson, S.B.: Current concepts in the pathogenesis of osteoarthritis. *Osteoarthritis. Cartilage*. **16 Suppl 3**, S1-3 (2008).
2. Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.P., Fahmi, H.: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol*. **7**, 33-42 (2011).
3. Goldring, M.B., Marcu, K.B.: Cartilage homeostasis in health and rheumatic diseases. *Arthritis Res Ther*. **11**, 224 (2009).
4. Sun, Y., Mauerhan, D.R., Kneisl, J.S., James Norton, H., Zinchenko, N., Ingram, J., et al.: Histological examination of collagen and proteoglycan changes in osteoarthritic menisci. *Open Rheumatol J*. **6**, 24-32 (2012).
5. Baffa, O., Cora, L., Americo, M., Fonseca, P., Oliveira, R., J, A.M.: Magnetic images of pharmaceutical dosage forms in the human gastrointestinal tract. *Conf Proc IEEE Eng Med Biol Soc*. **7**, 7254-7 (2005).
6. Colville-Nash, P.R., Willoughby, D.A.: COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. *Biorheology*. **39**, 171-9 (2002).
7. Verbruggen, G.: Chondroprotective drugs in degenerative joint diseases. *Rheumatology (Oxford)*. **45**, 129-38 (2006).
8. Hochberg, M.C., Dougados, M.: Pharmacological therapy of osteoarthritis. *Best Pract Res Clin Rheumatol*. **15**, 583-93 (2001).
9. Kubo, M., Ando, K., Mimura, T., Matsusue, Y., Mori, K.: Chondroitin sulfate for the treatment of hip and knee osteoarthritis: current status and future trends. *Life Sci*. **85**, 477-83 (2009).
10. Kamal-Eldin, A., Moazzami, A., Washi, S.: Sesame seed lignans: potent physiological modulators and possible ingredients in functional foods & nutraceuticals. *Recent Pat Food Nutr Agric*. **3**, 17-29 (2010).
11. Phitak, T., Pothacharoen, P., Settakorn, J., Poompimol, W., Caterson, B., Kongtawelert, P.: Chondroprotective and anti-inflammatory effects of sesamin. *Phytochemistry*. **80**, 77-88 (2012).
12. Miyake, Y., Fukumoto, S., Okada, M., Sakaida, K., Nakamura, Y., Osawa, T.: Antioxidative catechol lignans converted from sesamin and sesaminol triglucoside by culturing with *Aspergillus*. *J Agric Food Chem*. **53**, 22-7 (2005).
13. Miyawaki, T., Aono, H., Toyoda-Ono, Y., Maeda, H., Kiso, Y., Moriyama, K.: Antihypertensive effects of sesamin in humans. *J Nutr Sci Vitaminol (Tokyo)*. **55**, 87-91 (2009).
14. Miyahara, Y., Komiya, T., Katsuzaki, H., Imai, K., Nakagawa, M., Ishi, Y., et al.: Sesamin and episesamin induce apoptosis in human lymphoid leukemia Molt 4B cells. *Int J Mol Med*. **6**, 43-6 (2000).
15. Yamashita, K., Iizuka, Y., Imai, T., Namiki, M.: Sesame seed and its lignans produce marked enhancement of vitamin E activity in rats fed a low alpha-tocopherol diet. *Lipids*. **30**, 1019-28 (1995).

16. Nakabayashi, A., Kitagawa, Y., Suwa, Y., Akimoto, K., Asami, S., Shimizu, S., et al.: alpha-Tocopherol enhances the hypocholesterolemic action of sesamin in rats. *Int J Vitam Nutr Res.* **65**, 162-8 (1995).
17. Sirato-Yasumoto, S., Katsuta, M., Okuyama, Y., Takahashi, Y., Ide, T.: Effect of sesame seeds rich in sesamin and sesamol on fatty acid oxidation in rat liver. *J Agric Food Chem.* **49**, 2647-51 (2001).
18. Hou, R.C., Huang, H.M., Tzen, J.T., Jeng, K.C.: Protective effects of sesamin and sesamol on hypoxic neuronal and PC12 cells. *J Neurosci Res.* **74**, 123-33 (2003).
19. Bulow, H.E., Hobert, O.: The molecular diversity of glycosaminoglycans shapes animal development. *Annu. Rev. Cell. Dev. Biol.* **22**, 375-407 (2006).
20. Hu, G., Codina, M., Fisher, S.: Multiple enhancers associated with ACAN suggest highly redundant transcriptional regulation in cartilage. *Matrix Biol.* **31**, 328-37 (2012).
21. Mizumoto, S., Sugahara, K.: Bone and skin disorders caused by a disturbance in the biosynthesis of chondroitin sulfate and dermatan sulfate. In: *Extracellular matrix pathology and signaling* N. Karamanos. Ed. Berlin, Germany. De Gruyter 2012
22. Mizumoto, S., Ikegawa, S., Sugahara, K.: Human genetic disorders caused by mutations in the genes encoding biosynthetic enzymes for sulfated glycosaminoglycans. *J Biol Chem.* **288**, 10953-61 (2013).
23. Ambrosius, M., Kleesiek, K., Gotting, C.: The xylosyltransferase Iota gene polymorphism c.343G>T (p.A115S) is associated with decreased serum glycosaminoglycan levels. *Clin Biochem.* **42**, 1-4 (2009).
24. Cuellar, K., Chuong, H., Hubbell, S.M., Hinsdale, M.E.: Biosynthesis of chondroitin and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase II. *J Biol Chem.* **282**, 5195-200 (2007).
25. Kitagawa, H., Izumikawa, T., Uyama, T., Sugahara, K.: Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization. *J Biol Chem.* **278**, 23666-71 (2003).
26. Kitagawa, H., Uyama, T., Sugahara, K.: Molecular cloning and expression of a human chondroitin synthase. *J Biol Chem.* **276**, 38721-6 (2001).
27. Nakajima, M., Mizumoto, S., Miyake, N., Kogawa, R., Iida, A., Ito, H., Kitoh, H., Hirayama, A., Mitsubuchi, H., Miyazaki, O., Kosaki, R., Horikawa, R., Lai, A., Mendoza-Londono, R., Dupuis, L., Chitayat, D., Howard, A., Ferraz-Leal, G., Cavalcanti, D., Tsurusaki, Y., Saito, H., Watanabe, S., Lausch, E., Unger, S., Bonafe L., Ohashi, H., Superti-Furga, A., Matsumoto, N., Sugahara, K., Nishimura, G., and Ikegawa, S.: Mutations in B3GALT6 which encodes a glycosaminoglycan linker region enzyme cause a spectrum of skeletal and connective tissue disorders. *Am. J. Human Genetics.* **in press**, (2013).
28. Zimmermann, D.R., Dours-Zimmermann, M.T., Schubert, M., Bruckner-Tuderman, L., Heitz, P.U.: [Expression of the extracellular matrix proteoglycan, versican, in human skin]. *Verh. Dtsch. Ges. Pathol.* **78**, 481-4 (1994).
29. Goldring, M.B.: Human chondrocyte cultures as models of cartilage-specific gene regulation. *Methods Mol Med.* **107**, 69-95 (2005).
30. Al-Shanti, N., Saini, A., Stewart, C.E.: Two-Step versus One-Step RNA-to-CT 2-Step and One-Step RNA-to-CT 1-Step: validity, sensitivity, and efficiency. *J Biomol Tech.* **20**, 172-9 (2009).
31. Zimmermann, D.R., Dours-Zimmermann, M.T., Schubert, M., Bruckner-Tuderman, L., Heitz, P.U.: [Expression of the extracellular matrix proteoglycan, versican, in human skin]. *Verh Dtsch Ges Pathol.* **78**, 481-4 (1994).
32. Zimmermann, D.R., Ruoslahti, E.: Multiple domains of the large fibroblast proteoglycan, versican. *EMBO J.* **8**, 2975-81 (1989).
33. Kubo, M., Ando, K., Mimura, T., Matsusue, Y., Mori, K.: Chondroitin sulfate for the treatment of hip and knee osteoarthritis: current status and future trends. *Life. Sci.* **85**, 477-83 (2009).

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
34. Fidelix, T.S., Soares, B.G., Trevisani, V.F.: Diacerein for osteoarthritis. *Cochrane Database Syst Rev*. CD005117 (2006).
 35. Hunter, D.J., Wise, B.: Review: diacerein is more effective than placebo and is as effective as NSAIDs for knee and hip osteoarthritis. *Evid Based Med*. **12**, 74 (2007).
 36. Debord, P., Louchahi, K., Tod, M., Cournot, A., Perret, G., Petitjean, O.: Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. *Eur J Drug Metab Pharmacokinet*. **19**, 13-9 (1994).
 37. Pelletier, J.P., Yaron, M., Haraoui, B., Cohen, P., Nahir, M.A., Choquette, D., et al.: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. *Arthritis Rheum*. **43**, 2339-48 (2000).
 38. Hunter, C.J., Imler, S.M., Malaviya, P., Nerem, R.M., Levenston, M.E.: Mechanical compression alters gene expression and extracellular matrix synthesis by chondrocytes cultured in collagen I gels. *Biomaterials*. **23**, 1249-59 (2002).
 39. Shi, S., Mercer, S., Eckert, G.J., Trippel, S.B.: Regulation of articular chondrocyte aggrecan and collagen gene expression by multiple growth factor gene transfer. *J Orthop Res*. **30**, 1026-31 (2011).
 40. Chung, H.C., Lin, R.C., Logan, G.J., Alexander, I.E., Sachdev, P.S., Sidhu, K.S.: Human induced pluripotent stem cells derived under feeder-free conditions display unique cell cycle and DNA replication gene profiles. *Stem Cells Dev*. **21**, 206-16 (2011).
 41. Tew, S.R., Pothacharoen, P., Katopodi, T., Hardingham, T.E.: SOX9 transduction increases chondroitin sulfate synthesis in cultured human articular chondrocytes without altering glycosyltransferase and sulfotransferase transcription. *Biochem J*. **414**, 231-6 (2008).
 42. Prydz, K., Dalen, K.T.: Synthesis and sorting of proteoglycans. *J Cell Sci*. **113 Pt 2**, 193-205 (2000).
 43. Silbert, J.E., Sugumaran, G.: Biosynthesis of chondroitin/dermatan sulfate. *IUBMB Life*. **54**, 177-86 (2002).

Figure1
[Click here to download high resolution image](#)

Figure2
[Click here to download high resolution image](#)

Figure3
[Click here to download high resolution image](#)

Figure4

[Click here to download high resolution image](#)

Figure5

[Click here to download high resolution image](#)